ADA-EASD 2026 consensus favors earlier SGLT2/GLP-1 use in type 2 diabetes

The ADA and EASD updated their joint consensus statement on management of type 2 diabetes in nonpregnant adults, following a systematic review of literature since the 2022 update. The report broadens focus from hyperglycemia control to holistic management of long-term conditions associated with type 2 diabetes, and advocates earlier use, potentially from diagnosis, of SGLT2 inhibitors and/or GLP-1-based therapies for organ protection, with earlier combination use considered in those with concomitant cardiovascular disease, chronic kidney disease, or heart failure.

Most relevant for: Adults with type 2 diabetes, particularly those with concomitant cardiovascular disease, chronic kidney disease, or heart failure, managed by a multidisciplinary diabetes care team.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.